```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTASXJ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued
 NEWS 20  APR 15  WPIDS, WPINDEX, and WPIX enhanced with new
                  predefined hit display formats

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

FILE 'HOME' ENTERED AT 08:30:01 ON 25 APR 2008

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:30:13 ON 25 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2008 HIGHEST RN 1016892-81-1
DICTIONARY FILE UPDATES: 23 APR 2008 HIGHEST RN 1016892-81-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10539501.str



chain nodes :
17 18 19 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :

```
12-24  14-17  16-23  17-18  18-19  18-20  20-21  21-22
ring bonds :
1-2  1-6  1-12  2-3  3-4  4-5  5-6  5-7  6-10  7-8  7-13  8-9  8-16  9-10  10-11
11-12  13-14  14-15  15-16
exact/norm bonds :
1-12  5-7  6-10  7-8  7-13  8-9  8-16  9-10  10-11  11-12  13-14  14-15  15-16
16-23  17-18  18-19  18-20
exact bonds :
12-24  14-17  20-21  21-22
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 08:30:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       60 TO ITERATE

100.0% PROCESSED       60 ITERATIONS                          11 ANSWERS
SEARCH TIME: 00.00.01
```

L2 11 SEA SSS FUL L1

=> d l2 1-11

L2 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 775550-15-7 REGISTRY
ED Entered STN: 07 Nov 2004
CN Ergolinium, 9,10-didehydro-6,6-dimethyl-8-[(methyl-2-propynylamino)carbonyl]-, (8β)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H24 N3 O
CI COM
SR CA

Absolute stereochemistry.



L2 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 710279-03-1 REGISTRY
ED Entered STN: 15 Jul 2004
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N3 . x C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 160161-67-1
CMF C20 H23 N3

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 173214-84-1 REGISTRY
ED Entered STN: 14 Feb 1996
CN Ergoline-8-methanamine, 2-bromo-9,10-didehydro-N,6-dimethyl-N-(2-propynyl)-, (8β)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H22 Br N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 160161-67-1 REGISTRY
ED Entered STN: 13 Jan 1995
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propyn-1-yl-, (8β)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)- (9CI)
OTHER NAMES:
CN LEK 8829
FS STEREOSEARCH
MF C20 H23 N3
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PHAR, PROUSDDR, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 155340-39-9 REGISTRY
ED Entered STN: 26 May 1994
CN Ergoline-8-carboxamide, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ergoline-8-carboxamide, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1)
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
FS STEREOSEARCH
MF C20 H21 N3 O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 145204-77-9
CMF C20 H21 N3 O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 155340-33-3 REGISTRY
ED Entered STN: 26 May 1994
CN Ergoline-8-carboxamide, 9,10-didehydro-N-(1,1-diethyl-2-propynyl)-N,6-dimethyl-, (8α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
FS STEREOSEARCH
MF C24 H29 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 145204-81-5 REGISTRY
ED Entered STN: 07 Jan 1993
CN Ergolinium, 9,10-didehydro-6,6-dimethyl-8-[(methyl-2-propynylamino)carbonyl]-, chloride, (8β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergolinium deriv.
OTHER NAMES:
CN LEK 8827
FS STEREOSEARCH
MF C21 H24 N3 O . Cl
SR CA
LC STN Files: CA, CAPLUS
CRN (775550-15-7)

Absolute stereochemistry.



● Cl⁻

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 145204-80-4 REGISTRY
ED Entered STN: 07 Jan 1993
CN Ergoline-8-carboxamide, 2-bromo-9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)-, monomethanesulfonate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
OTHER NAMES:
CN LEK 8841
FS STEREOSEARCH
MF C20 H20 Br N3 O . C H4 O3 S
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, MEDLINE, TOXCENTER

CM 1

CRN 145204-79-1
CMF C20 H20 Br N3 O

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 145204-79-1 REGISTRY
ED Entered STN: 07 Jan 1993
CN Ergoline-8-carboxamide, 2-bromo-9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
FS STEREOSEARCH
MF C20 H20 Br N3 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 145204-78-0 REGISTRY
ED Entered STN: 07 Jan 1993
CN Ergoline-8-carboxamide, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)-, monomethanesulfonate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
OTHER NAMES:
CN LEK 8842
FS STEREOSEARCH
MF C20 H21 N3 O . C H4 O3 S
SR CA
LC STN Files: CA, CAPLUS, MEDLINE, TOXCENTER

CM 1

CRN 145204-77-9
CMF C20 H21 N3 O

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 145204-77-9 REGISTRY
ED Entered STN: 07 Jan 1993
CN Ergoline-8-carboxamide, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.
FS STEREOSEARCH
MF C20 H21 N3 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2 1-4

L2 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 775550-15-7 REGISTRY
ED Entered STN: 07 Nov 2004

CN Ergolinium, 9,10-didehydro-6,6-dimethyl-8-[(methyl-2-propynylamino)carbonyl]-, (8β)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H24 N3 O
CI COM
SR CA

Absolute stereochemistry.



L2 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 710279-03-1 REGISTRY
ED Entered STN: 15 Jul 2004
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N3 . x C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 160161-67-1
CMF C20 H23 N3

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 173214-84-1 REGISTRY
ED Entered STN: 14 Feb 1996
CN Ergoline-8-methanamine, 2-bromo-9,10-didehydro-N,6-dimethyl-N-(2-propynyl)-, (8β)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H22 Br N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2008 ACS on STN
RN 160161-67-1 REGISTRY
ED Entered STN: 13 Jan 1995
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propyn-1-yl-, (8β)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-, (8β)- (9CI)
OTHER NAMES:
CN LEK 8829

FS STEREOSEARCH
MF C20 H23 N3
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH,
      PHAR, PROUSDDR, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 710279-03-1/rn
L3 1 710279-03-1/RN

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 710279-03-1 REGISTRY
ED Entered STN: 15 Jul 2004
CN Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-,
    (8β)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N3 . x C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

    CM 1

    CRN 160161-67-1
    CMF C20 H23 N3

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 173214-84-1/rn
L4            1 173214-84-1/RN

=> d 14

L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   173214-84-1  REGISTRY
ED   Entered STN:  14 Feb 1996
CN   Ergoline-8-methanamine, 2-bromo-9,10-didehydro-N,6-dimethyl-N-(2-propynyl)-
     , (8β)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C20 H22 Br N3
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 160161-67-1
L5            1 160161-67-1
                (160161-67-1/RN)

=> d l5

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   160161-67-1  REGISTRY
ED   Entered STN:  13 Jan 1995
CN   Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propyn-1-yl-,
     (8β)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Ergoline-8-methanamine, 9,10-didehydro-N,6-dimethyl-N-2-propynyl-,
     (8β)- (9CI)
OTHER NAMES:
CN   LEK 8829
FS   STEREOSEARCH
MF   C20 H23 N3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH,
       PHAR, PROUSDDR, TOXCENTER, USPATFULL

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	218.50	218.71

FILE 'HCAPLUS' ENTERED AT 08:36:15 ON 25 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Apr 2008 VOL 148 ISS 18
FILE LAST UPDATED: 24 Apr 2008 (20080424/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 12 L5

=> d l6 1-12 ibib abs

L6 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:61168 HCAPLUS
DOCUMENT NUMBER: 146:169319

TITLE: Pharmaceutical composition for the treatment of disorders of sexual desire
INVENTOR(S): Ceci, Angelo; Mendla, Klaus
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007006738	A2	20070118	WO 2006-EP63991	20060706
WO 2007006738	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2614833	A1	20070118	CA 2006-2614833	20060706
PRIORITY APPLN. INFO.:			EP 2005-15110 A	20050712
			WO 2006-EP63991 W	20060706

OTHER SOURCE(S): MARPAT 146:169319
AB The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiol. functional derivative thereof for the manufacture of a medicament for the for the treatment of sexual desire disorders. A tablet contained a carbomethoxydichlorophenyltropane derivative 1.00, mannitol 121.50, maize starch 79.85, highly dispersed silicon dioxide 2.3, anhydrous 2.30, polyvidon k25 2.35, magnesium stearate and 3.00 mg.

L6 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1171443 HCAPLUS
DOCUMENT NUMBER: 143:432676
TITLE: New pharmaceutical compositions for the treatment of sexual disorders
INVENTOR(S): Mendla, Klaus; Pyke, Robert; Eisenreich, Wolfram; Friedl, Thomas
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbHH & Co. KG
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102342	A1	20051103	WO 2005-EP4081	20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005235422	A1	20051103	AU 2005-235422		20050418
CA 2563743	A1	20051103	CA 2005-2563743		20050418
EP 1740181	A1	20070110	EP 2005-736586		20050418

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

CN 1946404	A	20070411	CN 2005-80012692		20050418
BR 2005010074	A	20071016	BR 2005-10074		20050418
JP 2007533686	T	20071122	JP 2007-508810		20050418
US 20050245539	A1	20051103	US 2005-110449		20050420
IN 2006DN06048	A	20070427	IN 2006-DN6048		20061017
MX 2006PA12059	A	20070125	MX 2006-PA12059		20061018
KR 2007014184	A	20070131	KR 2006-724443		20061121
PRIORITY APPLN. INFO.:			US 2004-564662P	P	20040422
			US 2004-631800P	P	20041130
			WO 2005-EP4081	W	20050418

OTHER SOURCE(S): MARPAT 143:432676

AB The invention relates to new pharmaceutical compns. for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one addnl. active ingredient for the treatment of sexual disorders and methods for the preparation thereof.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:696745 HCAPLUS

DOCUMENT NUMBER: 143:199853

TITLE: Monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety for the sustained reduction of body weight

INVENTOR(S): Reess, Juergen; Raschig, Andreas; Pollentier, Stephane; Graff, Ole; Mikkelsen, Birgit Ohrt; Priskorn, Morten

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.; Neurosearch A/S

SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070427	A1	20050804	WO 2005-EP165	20050111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005205880	A1	20050804	AU 2005-205880		20050111
CA 2553649	A1	20050804	CA 2005-2553649		20050111
EP 1727547	A1	20061206	EP 2005-700803		20050111
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1905878	A	20070131	CN 2005-80001730		20050111
JP 2007519646	T	20070719	JP 2006-549961		20050111
US 20050203124	A1	20050915	US 2005-39991		20050121
MX 2006PA08205	A	20061020	MX 2006-PA8205		20060719
PRIORITY APPLN. INFO.:			EP 2004-1282	A	20040122
			EP 2004-5816	A	20040311
			WO 2005-EP165	W	20050111

OTHER SOURCE(S): MARPAT 143:199853
GI



I

AB The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiol. functional derivative thereof for the manufacture of a medicament for the sustained reduction of body weight
Thus, a tablet was prepared containing a tropane derivative (I) mg, mannitol 121.50 mg, maize starch 79.85 mg, highly dispersed anhydrous silicon dioxide 2.30 mg, Polyvidon K25 2.35 mg, magnesium stearate 3 mg.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:531357 HCAPLUS
DOCUMENT NUMBER: 141:65125
TITLE: Use of ergoline deriv LEK-8828 for the treatment of psychostimulant addiction
INVENTOR(S): Krisch, Igor; Zivin, Marko; Milivojevic, Natasa; Rucman, Rudolf; Bole, Breda; Urleb, Uros
PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004054578 A1 20040701 WO 2003-SI45 20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
SI 21351 A 20040630 SI 2002-305 20021217
AU 2003288888 A1 20040709 AU 2003-288888 20031211
EP 1581219 A1 20051005 EP 2003-781272 20031211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 200600147775 A1 20060119 US 2005-539501 20050902
PRIORITY APPLN. INFO.: SI 2002-305 A 20021217
WO 2003-SI45 W 20031211

AB The invention discloses a method for the treatment of psychostimulant addiction, in particular addiction to cocaine, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8β-aminomethylergoline (LEK 8829), in the form of the free base or a pharmaceutically acceptable addition salt, in particular the bimaleate salt. The invention also discloses pharmaceutical compns. containing this compound More particularly, the invention discloses a method of treatment for reduction of abstinence symptoms after cocaine withdrawal and for suppression the symptoms of craving for cocaine reinforcement, and to the use of the active substance for the preparation of the pharmaceutical composition for the treatment of cocaine addiction. In addition to the treatment of cocaine addiction, the invention also discloses a method for treatment of addiction with amphetamine, methamphetamine, dextroamphetamine, 3,4-methylenedioxymethamphetamine and pemoline, or acid addition salts thereof.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:466574 HCAPLUS
DOCUMENT NUMBER: 141:99539
TITLE: The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats
AUTHOR(S): Milivojevic, Natasa; Krisch, Igor; Sket, Dusan; Zivin, Marko
CORPORATE SOURCE: Institute of Pathophysiology, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2004), 369(6), 576-582
CODEN: NSAPCC; ISSN: 0028-1298
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Various dopaminergic drugs have been studied for their efficacy in the treatment of cocaine addiction. Pretreatment with either selective dopamine D1 receptor agonists or selective dopamine D2 receptor antagonists prevents reinstatement of cocaine-seeking in animal models of drug craving and relapse. We tested a novel ergoline derivative with combined D1 agonistic and D2 antagonistic effects, 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8β-aminomethylergoline bimaleate (LEK-8829), for its effects on cocaine-seeking in the i.v. cocaine self-administration

model in rats. Pretreatment with systemic injections of LEK-8829 attenuated reinstatement of cocaine-seeking induced by cocaine priming injections and diminished cocaine intake in cocaine self-administration sessions. LEK-8829 itself did not induce reinstatement of cocaine-seeking and did not maintain i.v. self-administration. The results of our study indicate that LEK-8829 is a candidate medication for the treatment of cocaine craving in cocaine addiction.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:86737 HCAPLUS
DOCUMENT NUMBER: 136:379981
TITLE: Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-Parkinsonian rats
AUTHOR(S): Glavan, Gordana; Sket, Dusan; Zivin, Marko
CORPORATE SOURCE: Brain Research Laboratory, Institute of Pathophysiology, School of Medicine, University of Ljubljana, Ljubljana, Slovenia
SOURCE: Molecular Pharmacology (2002), 61(2), 360-368
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Parkinsonism, a common unwanted side effect of typical antipsychotic (neuroleptic) drugs, is induced by the blockade of striatal dopamine D2 receptors. In rats with hemi-parkinsonism induced by unilateral lesion of dopaminergic nigrostriatal neurons with 6-hydroxydopamine, D2 antagonists inhibit contralateral turning induced by D2 agonists and augment the levels of neurotensin mRNA in dopaminergically intact striatum. By contrast, D1 agonists induce contralateral turning and augment neurotensin mRNA levels in dopamine-depleted striatum. These effects could be inhibited by D1 but not by D2 antagonists. Here we used a hemi-parkinsonian model to investigate the effects of putative D1 agonist/D2 antagonist LEK-8829 (9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate), an exptl. antipsychotic, on turning behavior and the expression of striatal neurotensin, preprotachykinin and neurotransmitter-induced early gene protein 4 (ania-4) mRNAs. We found that LEK-8829 inhibited contralateral turning induced by D2 agonist quinpirole, but only if the rats were cotreated with D1 antagonist SCH-23390. In situ hybridization showed that LEK-8829 induced the expression of neurotensin and ania-4 mRNAs in dopamine-intact striatum that could be completely blocked only by the combined treatment with SCH-23390 and quinpirole. In addition, LEK-8829 augmented the expression of neurotensin, preprotachykinin and ania-4 mRNAs in dopamine-depleted striatum that could be completely blocked by SCH-23390. This study clearly demonstrates that in hemi-parkinsonian rats D1 agonistic activity of LEK-8829 confers its anti-parkinsonian drug-like properties and modulates its neuroleptic drug-like properties, which are dependent on the blockade of dopamine D2 receptors. These findings imply that atypical antipsychotics with D1 intrinsic activity might have a reduced propensity for the induction of extrapyramidal syndrome.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:166094 HCAPLUS
DOCUMENT NUMBER: 130:332736
TITLE: Ergoline derivative LEK-8829-induced turning behavior

in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine
AUTHOR(S): Sprah, Lilijana; Zivin, Marko; Sket, Dusan
CORPORATE SOURCE: School of Medicine, Institute of Pathophysiology, University of Ljubljana, Ljubljana, Slovenia
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1999), 288(3), 1093-1100
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB LEK-8829 [9, 10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate] is an antagonist of dopamine D2 receptors and serotonin (5-HT)2 and 5-HT1A receptors in intact animals and a D1 receptor agonist in dopamine-depleted animals. In the present study, we used rats with unilateral striatal lesions with ibotenic acid (IA) to investigate the dopamine receptor activities of LEK-8829 in a model with innervated dopamine receptors. The IA-lesioned rats circled ipsilaterally when challenged with apomorphine, the mixed agonist on D1/D2 receptors. LEK-8829 induced a dose-dependent contralateral turning that was blocked by D1 receptor antagonist SCH-23390. The treatment with D1 receptor agonist SKF-82958 induced ipsilateral turning, whereas the treatment with D2 receptor antagonist haloperidol induced contralateral posture. The combined treatment with SKF-82958 and haloperidol resulted in a weak contralateral turning, indicating the possible receptor mechanism of contralateral turning induced by LEK-8829. Bromocriptine induced a weak ipsilateral turning that was blocked by haloperidol. The ipsilateral turning induced by bromocriptine was significantly potentiated by the coadministration of a low dose but not by a high dose of LEK-8829. The potentiation of turning was blocked either by SCH-23390 or by haloperidol. The potentiation of ipsilateral turning suggests the costimulation of D2 and D1 receptors by bromocriptine and LEK-8829, resp., whereas the lack of potentiation by the highest dose of LEK-8829 may be explained by the opposing activity of LEK-8829 and bromocriptine at D2 receptors. We propose that the D2 and 5HT2 receptor-blocking and D1 receptor-stimulating profile of LEK-8829 is promising for the treatment of neg. symptoms of schizophrenia.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:380599 HCAPLUS
DOCUMENT NUMBER: 129:117704
TITLE: Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine
AUTHOR(S): Zivin, Marko; Sprah, Lilijana; Sket, Dusan
CORPORATE SOURCE: School of Medicine, Institute of Pathophysiology, University of Ljubljana, Ljubljana, SI-1001, Slovenia
SOURCE: European Journal of Pharmacology (1998), 349(2/3), 151-157
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The ergoline derivative, LEK-8829 (9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline), has been proposed as a potential atypical antipsychotic drug with antagonistic actions at dopamine D2 and serotonin 5-HT2 and 5-HT1A receptors (Krisch et al., 1994, 1996). LEK-8829 also induces contralateral turning in rats with 6-hydroxydopamine-induced unilateral lesion of dopamine nigrostriatal neurons. Turning is blocked by SCH-23390 (R(+)-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-

1H-3-benzazepine), a dopamine D1 receptor antagonist. It has been suggested that LEK-8829 could have beneficial effects in parkinsonian patients suffering from psychotic episodes induced as a side-effect of antiparkinsonian treatment with dopamine D2 receptor agonists. Therefore, we now investigated the interaction of LEK-8829 with the dopamine D2 receptor agonist bromocriptine (2-bromo-α-ergokryptine) in 6-hydroxydopamine-lesioned rats. Treatment with either LEK-8829 (3 mg kg-1) or bromocriptine (3 mg kg-1) induced a vigorous contralateral turning response. The cumulated number of turns induced by the treatment with both drugs combined was not significantly different from the cumulated number of turns induced by single-drug treatment. The pretreatment with SCH-23390 (1 mg kg-1) did not have a significant effect on the bromocriptine-induced turning but significantly decreased the turning observed after the combined LEK-8829/bromocriptine treatment. We conclude that in the 6-hydroxydopamine model, the turning behavior mediated by the LEK-8829/bromocriptine combination may be the result of opposing activity of both drugs at dopamine D2 receptors with concomitant stimulation of dopamine D1 receptors by LEK-8829. Therefore, LEK-8829 may have a potential for the therapy of parkinsonism complicated by dopamine D2 receptor agonist drug-induced psychosis.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:749837 HCAPLUS
DOCUMENT NUMBER: 126:26280
TITLE: A new ergoline derivative, LEK-8829, as a potential new antipsychotic drug
AUTHOR(S): Krisch, Igor; Rucman, Rudolf; Lavric, Anton; Ocvirk, Magdalena; Bole-Vunduk, Breda
CORPORATE SOURCE: Departments Pharmacology, LEK Pharmaceutical and Chemical Company, Ljubljana, Slovenia
SOURCE: CNS Drug Reviews (1996), 2(3), 294-307
CODEN: CDREFB; ISSN: 1080-563X
PUBLISHER: Neva Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review, with 48 refs., of the chemical, action mechanism, and pharmacol. of a new ergoline derivative, LEK-8829, as a potential new antipsychotic.

L6 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:733464 HCAPLUS
DOCUMENT NUMBER: 126:14653
TITLE: The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions
AUTHOR(S): Zivin, Marko; Sprah, Lilijana; Sket, Dusan
CORPORATE SOURCE: School Medicine, Institute Pathophysiology, Ljubljana, 1000, Slovenia
SOURCE: British Journal of Pharmacology (1996), 119(6), 1187-1196
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Stockton
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Previous expts. have suggested a potential atypical antipsychotic activity of the ergoline derivative LEK-8829. In vitro expts. showed a high affinity to 5-HT1A, 5-HT2 and D2 receptors (the ratio of pKi values 5-HT2/D2=1.11) and a moderate affinity to D1 receptors. In vivo expts. showed antagonism of dopamine and 5-hydroxytryptamine (5-HT) receptor-linked behaviors. In the present study, the rats with unilateral dopaminergic deafferentation of the striatum, induced by the lesion of the median forebrain bundle with

6-hydroxydopamine (6-OHDA), were used to determine the effects of LED-8829 on turning behavior and on striatal c-fos mRNA levels. The administration of LED-8829 induced a long lasting contralateral turning behavior that was dose-dependent. It was found that the specific D1 receptor antagonist SCH-23390 but not the D2 receptor antagonist haloperidol or 5-HT1A antagonist pindolol, dose-dependently inhibited the turning behavior induced by LED-8829. In an attempt to clarify the D1:D2 receptor interactions involved in the action of LEK-8829 in the 6-OHDA model, we used in situ hybridization histochem. to compare the effect of SCH-23390 pretreatment on striatal c-fos mRNA expression induced either by LEK-8829 or by the typical antipsychotic haloperidol. LEK-8829 induced a bilateral striatal c-fos mRNA expression that was significantly higher in the denervated striatum as compared to the intact striatum and was completely blocked on both sides by pretreatment with SCH-23390. In contrast, haloperidol-induced striatal c-fos mRNA expression was limited to the innervated striatum and was not blocked by SCH-23390. Our data demonstrate an intrinsic activity of LEK-8829 on D1 receptors that is potentiated in the dopamine-depleted striatum. We conclude, therefore, that the putative atypical antipsychotic LEK-8829 may prove useful as an exptl. tool for the study of D1:D2 receptor interactions and could have beneficial effects in the treatment of drug-induced psychosis in patients with Parkinson's disease.

L6 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:71554 HCAPLUS
DOCUMENT NUMBER: 124:135717
TITLE: Ergoline derivatives of 2-propinylamine, a process for the manufacture thereof, and the use thereof for medicaments for treatment of psychosis
INVENTOR(S): Rucman, Rudolf; Bole-Vunduk, Breda; Ocvirk, Magdalena; Lavric, Bogomila; Krisch, Igor
PATENT ASSIGNEE(S): Lek Tovarna Farmacevtskih in Kemicnih Izdelkov, N.Sol.O., Slovenia
SOURCE: U.S., 7 pp. Cont.-in-part of U.S. 5,288,724. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5480885	A	19960102	US 1993-160271	19931202
US 5288724	A	19940222	US 1992-901983	19920622
PRIORITY APPLN. INFO.:			YU 1991-1154	A 19910701
			US 1992-901983	A2 19920622

OTHER SOURCE(S): MARPAT 124:135717
GI



I

AB A method of treating psychosis includes administering an antipsychotically effective amount of a 2-propinylamine ergolinyl derivative I [R1, R2, R3 = H, (branched) C1-6 alkyl; X = H, halo; Z = carbonyl, methylene; dotted line = single or double bond] or a diastereomeric form, racemate, or acid addition salt thereof. Preparation and pharmacol. and receptor-binding activity of e.g. 8β-Methyl-N-methyl-N-(2'propinyl)-6-methylergoline is included.

L6 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1995:188972 HCAPLUS
DOCUMENT NUMBER:	122:23624
TITLE:	Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841
AUTHOR(S):	Krisch, Igor; Bole-Vunduk, Breda; Pepelnak, Mojca; Lavric, Boza; Ocvirk, Alenka; Budihna, Metka V.; Sket, Dusan
CORPORATE SOURCE:	Dep. Pharmacol., LEK Pharmaceutical Chem. Co., Slovenia
SOURCE:	Journal of Pharmacology and Experimental Therapeutics (1994), 271(1), 343-52 CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER:	Williams & Wilkins
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The pharmacol. properties of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8β-aminomethylergoline (LEK-8829) and 9,10-didehydro-N-methyl-N-(2-propynyl)-2-bromo-6-methylergoline-8β-carboxamide (LEK-8841), new ergoline derivs., were compared with those of haloperidol and clozapine by in vitro radioligand displacement assays, various behavioral tests and blood pressure measurements. Both ergolines displayed low affinity for rat striatal 3H-SCH23390 (7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine)-labeled dopamine (D)1 binding sites and high affinity for striatal 3H-spiperone-labeled D2 and cortical 3H-ketanserin-labeled serotonin-2 (5-HT2) sites. The ratio of pKi values 5-HT2/D2 was 1.11 for LEK-8829 (close to that of clozapine, 1.13) and 0.98 for LEK-8841 (close to that of haloperidol, 0.95). All compds. inhibited apomorphine-induced locomotor activity in rats, apomorphine-induced climbing behavior in mice and 5-hydroxytryptophan-induced head twitches in mice and induced catalepsy in rats and in mice. LEK-8829 and clozapine, but not LEK-8841 and haloperidol, showed a certain degree of mesolimbic selectivity, i.e., they caused more potent inhibition of apomorphine-induced locomotion compared with the induction of catalepsy in rats. In the case of LEK-8829, nonspecific effects that presumably predict a side effect profile, such as potentiation of pentobarbital-induced anesthesia in mice (sedation), antagonism of oxotremorine-induced tremors in mice (anticholinergic activity),

spontaneous locomotor activity in mice and norepinephrine-induced lethality in rats (sedation and hypotension), were relatively weak compared with the activities described earlier. In contrast, LEK-8841 showed nonspecific effects at the similar dose levels as dopamine and 5-HT antagonistic effects. The results of direct measurements of the influences of both compds. on blood pressure agreed with the previously mentioned findings, i.e., LEK-8829 was relatively less hypotensive than LEK-8841 was. It is suggested that LEK-8829 might be an efficient antipsychotic with a reduced propensity to cause sedative, anticholinergic and hypotensive side effects. A certain degree of mesolimbic selectivity also points toward the possibility of a reduced propensity to cause extrapyramidal symptoms. In contrast, in regard to side effects (including extrapyramidal symptoms), the profile of LEK-8841 is less promising.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.75	272.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.60	-9.60

FILE 'STNGUIDE' ENTERED AT 08:40:20 ON 25 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 18, 2008 (20080418/UP).

=>